- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: ang 1-7 | angiotensin 1-7 | TXA-127 | TXA127
Compound class: Endogenous peptide in human, mouse or rat
Comment: Angiotensin (1-7) is a naturally occurring peptide that is cleaved from angiotensin 1 or angiotensin 2 by the actions of the enzymes ACE2 and MME respectively.
Species: Human, Mouse, Rat
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|A pharmaceutical formulation of angiotensin (1-7) known as a TXA127 was advanced as a therapeutic by Tarix Pharmaceuticals for the management of rare neuromuscular and connective tissue diseases. Click here to link to ClinicalTrials.gov's full list of TXA127 trials. In June 2017 the EMA granted TXA127 orphan drug designation for the treatment of epidermolysis bullosa.
SARS-CoV-2 and COVID-19: In response to the COVID-19 pandemic, trials of angiotensin (1-7) in patients with severe COVID-19 were initiated, to determine if administration of angiotensin (1-7) might prevent acute kidney injury and deterioration into multi-organ failure in these patients. The proposition is that exogenous angiotensin (1-7) would normalise the angiotensin II/ angiotensin (1-7) balance that is disrupted by SARS-CoV-2 binding to ACE2 (loss of ACE2 > elevated/excessive angiotensin II > tissue injury).
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT04332666||Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial||Phase 2/Phase 3 Interventional||Erasme University Hospital|
|NCT04401423||TXA127 for the Treatment of Severe COVID-19||Phase 2 Interventional||Columbia University|